JP2016501876A - ステロイドの抗痙攣活性 - Google Patents

ステロイドの抗痙攣活性 Download PDF

Info

Publication number
JP2016501876A
JP2016501876A JP2015545458A JP2015545458A JP2016501876A JP 2016501876 A JP2016501876 A JP 2016501876A JP 2015545458 A JP2015545458 A JP 2015545458A JP 2015545458 A JP2015545458 A JP 2015545458A JP 2016501876 A JP2016501876 A JP 2016501876A
Authority
JP
Japan
Prior art keywords
steroid
allopregnanolone
subject
seizure
neurosteroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015545458A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501876A5 (enExample
Inventor
マイケル エイ． ロゴースキ
マイケル エイ． ロゴースキ
ドロタ ゾルコウスカ
ドロタ ゾルコウスカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2016501876A publication Critical patent/JP2016501876A/ja
Publication of JP2016501876A5 publication Critical patent/JP2016501876A5/ja
Priority to JP2018131186A priority Critical patent/JP6966981B2/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2015545458A 2012-11-30 2013-11-27 ステロイドの抗痙攣活性 Withdrawn JP2016501876A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018131186A JP6966981B2 (ja) 2012-11-30 2018-07-11 ステロイドの抗痙攣活性

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261732252P 2012-11-30 2012-11-30
US61/732,252 2012-11-30
PCT/US2013/072351 WO2014085668A1 (en) 2012-11-30 2013-11-27 Anticonvulsant activity of steroids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018131186A Division JP6966981B2 (ja) 2012-11-30 2018-07-11 ステロイドの抗痙攣活性

Publications (2)

Publication Number Publication Date
JP2016501876A true JP2016501876A (ja) 2016-01-21
JP2016501876A5 JP2016501876A5 (enExample) 2017-01-05

Family

ID=50828483

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015545458A Withdrawn JP2016501876A (ja) 2012-11-30 2013-11-27 ステロイドの抗痙攣活性
JP2018131186A Active JP6966981B2 (ja) 2012-11-30 2018-07-11 ステロイドの抗痙攣活性
JP2021108255A Active JP7744166B2 (ja) 2012-11-30 2021-06-30 ステロイドの抗痙攣活性
JP2023125962A Pending JP2023133494A (ja) 2012-11-30 2023-08-02 ステロイドの抗痙攣活性

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018131186A Active JP6966981B2 (ja) 2012-11-30 2018-07-11 ステロイドの抗痙攣活性
JP2021108255A Active JP7744166B2 (ja) 2012-11-30 2021-06-30 ステロイドの抗痙攣活性
JP2023125962A Pending JP2023133494A (ja) 2012-11-30 2023-08-02 ステロイドの抗痙攣活性

Country Status (7)

Country Link
US (6) US20150313915A1 (enExample)
EP (2) EP2925327B1 (enExample)
JP (4) JP2016501876A (enExample)
AU (4) AU2013352141B2 (enExample)
DK (1) DK2925327T3 (enExample)
ES (1) ES2973320T3 (enExample)
WO (1) WO2014085668A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023055802A (ja) * 2017-09-05 2023-04-18 イーグル ファーマスーティカルズ、インク． ダントロレンを使用して神経薬暴露を治療する方法

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120107533A (ko) 2005-11-28 2012-10-02 마리누스 파마슈티컬스 ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
HRP20192348T1 (hr) * 2012-01-23 2020-03-20 Sage Therapeutics, Inc. Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil eter beta-ciklodekstrina
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
KR102121633B1 (ko) 2012-08-21 2020-06-10 세이지 테라퓨틱스, 인크. 간질 또는 간질지속 상태를 치료하는 방법
DK2925327T3 (da) 2012-11-30 2024-03-25 Univ California Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression
EP2986623B1 (en) 2013-04-17 2018-11-07 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) * 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
CN107206097A (zh) * 2014-11-18 2017-09-26 皮克萨尔比奥公司 用于治疗急性、术后或慢性疼痛的组合物及其使用方法
HUE049014T2 (hu) 2014-11-27 2020-09-28 Sage Therapeutics Inc Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére
WO2016127170A1 (en) * 2015-02-06 2016-08-11 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
EP3280420B1 (en) * 2015-04-10 2024-03-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MA45276A (fr) * 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
AU2016295138B2 (en) * 2015-07-17 2021-11-04 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
KR20180052611A (ko) 2015-08-18 2018-05-18 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 영상화 및 치료 용도를 위한 니트록사이드 함유 아밀로이드 결합 제제
EP3362042A1 (en) 2015-10-16 2018-08-22 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
CA3017172C (en) * 2016-03-08 2023-03-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10858338B2 (en) 2016-03-15 2020-12-08 The Regents Of The University Of California Inhibitors for soluble epoxide hydrolase (SEH) and fatty acid amide hydrolase (FAAH)
CN119112906A (zh) 2016-08-11 2024-12-13 奥维德医疗公司 用于治疗癫痫性紊乱的方法和组合物
IL315950A (en) 2016-08-23 2024-11-01 Sage Therapeutics Inc 19-NOR C3, 3-Dimuter C21-N-Pyrazolyl Steroid Crystalline
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
EP3946358A4 (en) * 2019-04-05 2022-12-28 The Regents of The University of California ALLOPREGNANOLON COMPOSITIONS AND USES THEREOF
SG11202112111WA (en) 2019-05-10 2021-11-29 Brii Biosciences Inc Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof
JP7754799B2 (ja) 2019-08-05 2025-10-15 マリナス ファーマシューティカルズ， インコーポレイテッド てんかん重積状態の治療に使用するためのガナキソロン
EP4072559A4 (en) 2019-12-06 2023-06-21 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX
PE20221911A1 (es) 2020-03-25 2022-12-23 Sage Therapeutics Inc Uso de agentes para el tratamiento de condiciones respiratorias
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US12208103B1 (en) * 2021-05-07 2025-01-28 Lipocine Inc. Compositions and methods for treating CNS disorders
US12005185B2 (en) 2021-12-17 2024-06-11 Belhaven BioPharma Inc. Medical counter measures including dry powder formulations and associated methods
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080269183A1 (en) * 2004-09-27 2008-10-30 The Regents Of The University Of California Novel Therapy for Treatment of Chronic Degenerative Brain Diseases and Nervous System Injury
JP2009524582A (ja) * 2005-11-28 2009-07-02 マリナス ファーマシューティカルズ ガナキソロン製剤、およびその作製方法、およびその使用
WO2013112605A2 (en) * 2012-01-23 2013-08-01 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating cns disorders

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865939A (en) 1973-02-23 1975-02-11 Procter & Gamble Edible oils having hypocholesterolemic properties
SE8600632D0 (sv) 1986-02-13 1986-02-13 Kabivitrum Ab Novel pharmaceutical composition
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
DE69435286D1 (de) 1993-05-24 2010-05-20 Purdue Pharma Ltd Verfahren und zusammensetzungen zum hervorrufen von schlaf
DE69518509T2 (de) 1994-02-14 2001-04-19 Euro-Celtique S.A., Luxemburg/Luxembourg Androstane und pregnane zur allosterischen modulation des gaba-rezeptors
WO1996016076A1 (en) 1994-11-23 1996-05-30 Cocensys, Inc. Androstane and pregnane series for allosteric modulation of gaba receptor
US6780853B1 (en) 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
CZ394197A3 (cs) 1995-06-06 1998-06-17 Cocensys, Inc. Neuroaktivní steroidy androstanové a pregnanové řady
EP0840612A1 (en) 1995-07-24 1998-05-13 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
US7630757B2 (en) 1997-01-06 2009-12-08 Flint Hills Scientific Llc System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject
US6245757B1 (en) 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
JP3877961B2 (ja) * 1998-03-11 2007-02-07 ベクストルム，トルビエーン Ｃｎｓ疾患の治療におけるエピアロプレグナノロン
EP1175390B1 (en) 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US20020072509A1 (en) 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
US6737043B2 (en) 2001-05-24 2004-05-18 Alexza Molecula Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
EP1392260A2 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of benzodiazepines through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
JP2003063965A (ja) 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
US8354438B2 (en) 2001-08-08 2013-01-15 Michael Chez Neurological functions
WO2004019953A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
US7781421B2 (en) 2003-05-29 2010-08-24 Washington University Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods
US7816074B2 (en) 2003-07-31 2010-10-19 The Research Foundation Of State University Of New York α4 β2 δGABA-A receptors as a strategy for PMS and alcoholism
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
WO2006034196A1 (en) 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
EA013433B1 (ru) 2005-02-15 2010-04-30 Элан Фарма Интернэшнл Лтд. Аэрозольные и впрыскиваемые рецептуры лекарственных препаратов бензодиазепина, состоящего из наночастиц
WO2006102644A2 (en) 2005-03-24 2006-09-28 Emory University Methods for the treatment of central nervous system injury via a tapered administration of progesterone
JP2008538748A (ja) 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド 不安、物質乱用及び依存の予防のための改良型方法及び組成物
US20110319386A1 (en) 2005-08-26 2011-12-29 Braincells Inc. Neurogenesis by muscarinic receptor modulation
US20070287931A1 (en) 2006-02-14 2007-12-13 Dilorenzo Daniel J Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
US20080026918A1 (en) * 2006-07-27 2008-01-31 Michael Lemke Athletic training device with multi-directional movement
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
US20090074677A1 (en) 2007-01-08 2009-03-19 Duke University Neuroactive steroid compositions and methods of use therefor
US20090203658A1 (en) 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
US7813811B2 (en) 2007-02-08 2010-10-12 Neuropace, Inc. Refillable reservoir lead systems
US20080243022A1 (en) 2007-03-30 2008-10-02 Donnett James G Seizure prediction using brain signal telemetry
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
EP2167098B1 (en) 2007-06-11 2018-09-05 University Of Southern California Allopregnanolone in a method for enhancing neurological function (alzheimer disease)
JP5663303B2 (ja) * 2007-06-15 2015-02-04 リサーチ トライアングル インスティテュート Ｇａｂａレセプタークロライドイオノフォアの潜在的アロステリック調節特性を有するアンドロスタンステロイドおよびプレグナンステロイド
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
EP2175886A1 (en) 2007-06-28 2010-04-21 CNSBio Pty Ltd Combination methods and compositions for treatment of neuropathic pain
US9788744B2 (en) 2007-07-27 2017-10-17 Cyberonics, Inc. Systems for monitoring brain activity and patient advisory device
US20100297181A1 (en) 2007-12-26 2010-11-25 Eisai R&D Management Co., Ltd. AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
US20090198145A1 (en) 2008-02-06 2009-08-06 Chow Harrison Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
US8729070B2 (en) 2008-02-20 2014-05-20 Targia Pharmaceuticals CNS pharmaceutical compositions and methods of use
ES2617873T3 (es) 2008-10-10 2017-06-20 Vm Discovery, Inc. Composiciones y métodos para tratar trastornos de alcoholismo, dolor y otras enfermedades
CN102300566A (zh) 2008-11-30 2011-12-28 O·扎查尔 血管收缩剂的皮肤应用
EP2369986A4 (en) 2008-12-23 2013-08-28 Neurovista Corp BRAIN STATUS ANALYSIS BASED ON SELECTED ANTI-BREAKING CHARACTERISTICS AND CLINICAL MANIFESTATIONS
US20110306579A1 (en) 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
ES2525257T3 (es) * 2009-02-25 2014-12-19 Supratek Pharma, Inc. Composiciones de ciclopolisacárido y de bendamustina
WO2010107922A1 (en) 2009-03-17 2010-09-23 Duke University Neuroactive steroid compositions and methods of use for lowering cholesterol
US20110152840A1 (en) 2009-12-23 2011-06-23 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
HRP20171699T1 (hr) 2010-01-21 2018-01-26 Drawbridge Pharmaceuticals Pty Ltd. Formulacija anestetika
CA2816806A1 (en) 2010-11-03 2012-05-10 Sanofi-Aventis Deutschland Gmbh Needle cannula containing medicament
US20130309306A1 (en) 2010-12-01 2013-11-21 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
US9084797B2 (en) 2011-05-23 2015-07-21 Besins Healthcare Luxembourg Sarl Progesterone treatment for improving sleep quality
KR20130002292A (ko) 2011-06-28 2013-01-07 주식회사 비보존 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
WO2013019711A2 (en) 2011-07-29 2013-02-07 The Regents Of The University Of California NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
CN107936076B (zh) 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
AU2012323888A1 (en) 2011-10-14 2014-05-29 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
KR20140098811A (ko) 2011-11-29 2014-08-08 가부시키가이샤 아미노 압 가가쿠 신경 및/또는 인지 기능에 대한 유익한 효과를 갖는 비세닌-2를 포함하는 조성물
WO2013188792A2 (en) 2012-06-15 2013-12-19 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
KR102121633B1 (ko) 2012-08-21 2020-06-10 세이지 테라퓨틱스, 인크. 간질 또는 간질지속 상태를 치료하는 방법
US9757391B2 (en) 2012-11-09 2017-09-12 Goodchild Investments Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
DK2925327T3 (da) 2012-11-30 2024-03-25 Univ California Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression
WO2014108808A2 (en) 2013-01-09 2014-07-17 Henry James Lorne Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
KR20180054796A (ko) 2015-10-14 2018-05-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 베타 세포 복제 및/또는 생존의 향상
CA3017172C (en) 2016-03-08 2023-03-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US20180050005A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
US20180050107A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Neurosteroid compositions and methods of use thereof
AU2017324262B2 (en) 2016-09-07 2023-06-22 Glia, Llc Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080269183A1 (en) * 2004-09-27 2008-10-30 The Regents Of The University Of California Novel Therapy for Treatment of Chronic Degenerative Brain Diseases and Nervous System Injury
JP2009524582A (ja) * 2005-11-28 2009-07-02 マリナス ファーマシューティカルズ ガナキソロン製剤、およびその作製方法、およびその使用
WO2013112605A2 (en) * 2012-01-23 2013-08-01 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating cns disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023055802A (ja) * 2017-09-05 2023-04-18 イーグル ファーマスーティカルズ、インク． ダントロレンを使用して神経薬暴露を治療する方法

Also Published As

Publication number Publication date
WO2014085668A1 (en) 2014-06-05
CA2892811A1 (en) 2014-06-05
JP2021152074A (ja) 2021-09-30
EP2925327A1 (en) 2015-10-07
DK2925327T3 (da) 2024-03-25
AU2013352141A1 (en) 2015-06-18
US20210100817A1 (en) 2021-04-08
US10251894B2 (en) 2019-04-09
AU2018204865A1 (en) 2018-07-19
ES2973320T3 (es) 2024-06-19
EP4335505A2 (en) 2024-03-13
US20190142845A1 (en) 2019-05-16
AU2022202943A1 (en) 2022-05-26
AU2020201919B2 (en) 2022-02-10
US20180193357A1 (en) 2018-07-12
US20180133229A1 (en) 2018-05-17
US20150313915A1 (en) 2015-11-05
EP2925327A4 (en) 2016-06-01
AU2018204865B2 (en) 2019-12-19
AU2020201919A1 (en) 2020-04-02
US20240197754A1 (en) 2024-06-20
JP6966981B2 (ja) 2021-11-17
EP2925327B1 (en) 2024-01-10
JP7744166B2 (ja) 2025-09-25
AU2013352141B2 (en) 2018-04-05
EP4335505A3 (en) 2024-06-05
JP2018193377A (ja) 2018-12-06
JP2023133494A (ja) 2023-09-22
AU2022202943B2 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
JP7744166B2 (ja) ステロイドの抗痙攣活性
US20200030304A1 (en) Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers
US10478505B2 (en) Edible oils to enhance delivery of orally administered steroids
ES2875742T3 (es) Métodos para aumentar la inhibición tónica y tratamiento del síndrome de Angelman
US20180153906A1 (en) Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
JP2001526210A (ja) 親油性糖質副腎皮質ステロイドおよび界面活性剤を１つだけ含有するミセルを含んでなる医薬組成物
EP3267978B1 (en) Topical compositions comprising a corticosteroid
BR112014003651B1 (pt) Dispositivos mucoadesivos resistentes ao mau uso para a liberação de buprenorfina
WO2021209025A1 (en) Pharmaceutical compositions
JP2012505236A (ja) コルチコステロイド組成物およびそれの治療方法
CA2892811C (en) Allopregnanolone and a sulfobutylether-b-cyclodextrin salt for the treatment of post-partum depression
TW201505635A (zh) 治療潰瘍性結腸炎之方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180815

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180816

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180907

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190205